Zobrazeno 1 - 5
of 5
pro vyhledávání: '"Chiara Malmberg"'
Autor:
Konrad Nilsson, Stefan James, Oskar Angerås, Jenny Backes, Henrik Bjursten, Pascal Candolfi, Mattias Götberg, Henrik Hagström, Chiara Malmberg, Niels Erik Nielsen, Archita Sarmah, Magnus Settergren, Tom Bromilow
Publikováno v:
Upsala Journal of Medical Sciences, Vol 129, Pp 1-10 (2024)
Background: Transcatheter aortic valve implantation (TAVI) has shown similar or improved clinical outcomes compared with surgical aortic valve replacement (SAVR) in patients with symptomatic severe aortic stenosis at low risk for surgical mortality.
Externí odkaz:
https://doaj.org/article/5a02299bc043427695aa304e6d0c949f
Publikováno v:
Frontiers in Medicine, Vol 10 (2023)
ObjectivesBiomarker testing is indispensable for the implementation of precision medicine (PM) in oncology. The aim of this study was to assess the value of biomarker testing from a holistic perspective based on the example of advanced non-small cell
Externí odkaz:
https://doaj.org/article/64c871fe46f0483889a7f022c1759496
Autor:
Susanne Hartz, Christophe Sapin, Bernd Schweikert, Chiara Malmberg, Mercedes Núñez, Tatiana Dilla
Publikováno v:
BMJ Open, Vol 10, Iss 8 (2020)
Externí odkaz:
https://doaj.org/article/6ebbbc3e135f47f6a7147a057648c82d
Autor:
Bernd Schweikert, Gayathri Kumar, Susanne Hartz, Debby Nott, Sandeep Kiri, Christophe Sapin, Örjan Åkerborg, Chiara Malmberg
Publikováno v:
PharmacoEconomics Open
Background Interleukin-17A (IL-17A) antagonists are a recent innovation for treating psoriatic arthritis (PsA). There are currently no cost-effectiveness analyses (CEAs) comparing the IL-17A antagonists ixekizumab and secukinumab in PsA from a UK per
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f03e40003468af7b35391ea5c18d5b8f
http://europepmc.org/articles/PMC7688884
http://europepmc.org/articles/PMC7688884
Autor:
Mercedes Núñez, Tatiana Dilla, Susanne Hartz, Chiara Malmberg, Bernd Schweikert, Christophe Sapin
Publikováno v:
BMJ Open
BMJ Open, Vol 10, Iss 8 (2020)
BMJ Open, Vol 10, Iss 8 (2020)
ObjectiveTo conduct a cost-effectiveness analysis from the perspective of the Spanish National Health System (NHS) comparing ixekizumab versus secukinumab.DesignA Markov model with a lifetime horizon and monthly cycles was developed based on the York
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::23a39978c197a2f845edd236a64d7e12
https://doi.org/10.1136/bmjopen-2019-032552
https://doi.org/10.1136/bmjopen-2019-032552